1. Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy
   Ye Chen et al, 2022, Biomedicine & Pharmacotherapy CrossRef
2. Doxorubicin-mediated cardiac dysfunction: Revisiting molecular interactions, pharmacological compounds and (nano)theranostic platforms
   Xiaofeng Li, 2023, Environmental Research CrossRef
3. Exploration of the Mechanism of Shengxian Decoction Against Chronic Obstructive Pulmonary Disease Based on Network Pharmacology and Experimental Verification
   Yifei Chen et al, 2023, ASSAY and Drug Development Technologies CrossRef
4. Role and molecular mechanism of traditional Chinese medicine in preventing cardiotoxicity associated with chemoradiotherapy
   Xin-Fang Lv et al, 2022, Frontiers in Cardiovascular Medicine CrossRef
5. Echinacoside ameliorates doxorubicin‑induced cardiac injury by regulating GPX4 inhibition‑induced ferroptosis
   Yan Ma et al, 2023, Experimental and Therapeutic Medicine CrossRef
6. METTL14 promotes doxorubicin-induced cardiomyocyte ferroptosis by regulating the KCNQ1OT1-miR-7-5p-TFRC axis
   Shaowei Zhuang et al, 2023, Cell Biology and Toxicology CrossRef
7. Chemical and Biological Evidence of the Efficacy of Shengxian Decoction for Treating Human Lung Adenocarcinoma
   Kejuan Li et al, 2022, Frontiers in Oncology CrossRef
8. Targeting Oxidative Stress, NLRP3 Inflammasome, and Autophagy by Fraxetin to Combat Doxorubicin-Induced Cardiotoxicity
   Ahmed M. Kabel et al, 2021, Pharmaceuticals CrossRef
9. Shengxian decoction protects against chronic heart failure in a rat model via energy regulation mechanisms
   Ze-Qi Yang et al, 2023, BMC Complementary Medicine and Therapies CrossRef